Page 1,001«..1020..1,0001,0011,0021,003..1,0101,020..»

Interview with Temple Grandin: Autism, genetics and the steep price of being intelligent – Salon

Posted: June 1, 2020 at 6:47 pm

Those who follow the science behind autism may know that there is an explosion of scientific research happening in the field right now.In January Mount Sinai Hospital published a study that identified 102 genes associated with autism. A paper published in Biological Psychiatry earlier this month suggests that a gene mutation may be linked to autistic behaviors. And arecent government studyfound that children who have an autistic uncle or aunt have a more than doubled risk of being diagnosed with the condition themselves.

At the crux of these studies and so many others are questions about why some people have this very unique type of brain. If you're on the autism spectrum, you're likely to be more intelligent than average, but also to struggle more in social situations. You have skills that can make you excel in many career paths, but are also more likely to face very unique types of employment-based discrimination along the way.

What causes people to develop like this? Is it in our genes, due to environmental factors or caused by some combination of both factors? This question, known colloquially as the "nature versus nurture" debate in biology, is innate to much psychology and sociobiology research. To wit: intelligence, disorders like ADHD, and personality disorders all have aspects that are develpmental or environmental and aspects that are genetic.

To learn more about new research in thenature versus nurture debate for autism, I turned to Temple Grandin for answers and this is the part where I need to add that I'm not neutral about Temple Grandin.

The advocate of humane treatment for livestock, who was the focus of the 2010 movie "Temple Grandin" starring Claire Danes, is a hero of the autism community, for which she has emerged as a major spokesperson. I am also on the autism spectrum and, as such, she is a person to whom I have reached out more than once about questions about issues facing my community. She is unquestionably brilliant, blunt to a fault, passionate about helping people and animals and yet clearly one who does not suffer fools gladly.

She also, as I quickly learned, has a talent for explaining autism in a way that makes it easy for virtually anyone to understand. I suspect the readers of this interview will agree. As always, this interview has been condensed and edited for print.

Let's talk about the genetics of autism. We were talking about a January study done at Mt. Sinai Hospital which found that there are 102 genes associated with autism. Do you tend to agree with it?

Well I have no reason not to agree with the study. Basically, autism is a continuous trait. There's a lot of traits where many many genes contribute just a little bit....Some of the genes were associated with other types of developmental delays. There's also a lot of research that shows that there's a crossover between ADHD and autism. Even in the brain scans, there is crossover. I've got some of those references in the new edition of "The Way I See It." Basically, you have a whole lot of little tiny code variations that contribute a little bit and they all have to do with brain development.

Now, I've told you about my own genome scanning. My genes have been totally scanned. What I found is other health problems I have anxiety, bad skin, bad teeth that showed right up. Simple genetics. But the autism stuff, yeah, I got some of the at-risk genes. It gets back into basic brain development.

I told you about the paper called"Genomic Trade-Offs: Are Autism and Schizophrenia the Steep Price of the Human Brain?" This is a quote from their abstract this isn't the way I would have put it but they said, "The genes that make us mad, make us human." That's a quote out of the abstract of the paper. It's not me saying that. I say that the same genes that make the brain big are also involved with autism and schizophrenia. It's a whole lot of little genes. It's a whole lot of little, I call them code variations. There's actually some argument in the literature to exactly what a gene is. I mean there's simple genetic stuff like brown or black coats on Angus cattle. That's very very simple genetics. That's Mendelian genetics. You need to forget about that.

I also went back and looked up some of the twin studies. Some of these were done ages ago. I found a nice review article on "Heritability of Autism Spectrum Disorders: A Meta-analysis of Twin Studies." It's a nice review article on twin studies. Some of this research is very old.

It sounds like you're saying that you believe nature plays a larger role than nurture in creating autism?

Yes. When it comes to nature, what's been found in twin studies, that when child is brought up anywhere resembling a decent environment, there's a lot of traits where genetics has a big effect on it. You get into a lot of things across the board. I'm going to say a person, what they become, is half-nature and half-nurture. It's the same thing with an animal. Some traits are much more genetic than others. One trait that's really genetic is the tendency to startle. This is true with cattle and horses, like if you open an umbrella suddenly, some horses are going to rear up and hit the roof and others will just flinch. Now what context are you discussing nature and nurture?

I'm talking about the question of when people are born on the autism spectrum, to what degree is that because of their genes and to what degree is that because of environmental factors that influence their neurological development, like the way their raised, the degree to which they're exposed to various potentially intellectually stimulating stimuli, things like that.

Well those things all have an effect. Let's say you took a young autistic kid like me and you did no early intervention. I don't think I would have become a college professor. So in terms of what you might become, maybe I'd be in an institution somewhere if nothing had been done with me.

I wonder the same thing about myself.

Well this is the problem, you see? This is something I tell parents all the time: I talk to a lot of low income families and say, You got a kid, he's two-and-a-half or three years old, he's not talking, he sits in the corner rocking, you've got a problem. I don't care whether you've got an official diagnosis or not, work with this kid now. I suggest that they go to their church group and get some volunteers, and you need to start taking turns playing games with the kid. Just start teaching him words, get down to work with this kids. If he just sits there and vegetates, he ain't going anywhere. So okay, that's an environmental influence there.

But then there's other kids that don't work as hard. Some of them can learn to type independently. I mean both nature and nurture are important in determining what a person could accomplish.

I'm going to just take it animals and people both, I'm going to say half-and-half, in terms of what you become. I talk to educators about the goal of education and say, let's look at where a student is 10 years after high school. Well, 10 years after high school I was doing that big dip vat project that was shown in the movie. That was 10 years after high school almost exactly. Okay if the kid's ending up in jail or some other bad thing, certainly don't want him there.

From a cultural perspective, what do you think the implications of this are? Obviously the science is pretty cut and dried. In terms of how society views people who are intelligent [but] also display non-neurotypical traits, do you think this paper could possibly change the way we perceive those who are on the spectrum?

First of all, I never told anyone I had autism. You know what my biggest barrier was in the '70s in the feedlot industry, the cattle industry, in Arizona in the '70s? Being a woman. Much bigger barrier than autism ever was. Being a woman was the biggest barrier. I got kicked out of places for being a woman.

So you're saying that's a much bigger barrier for you than being on the spectrum?

For much of my career, a much bigger barrier. Early 1970s, I want to emphasize early '70s, much bigger barrier, much bigger barrier. This is the early '70s when I started.

And the way, what I did is I had to prove to them. I had to be three times better than a guy. The thing that I got people to accept me is when I showed my work. I would lay the drawings out. I'd go in for an interview and I'd take a big drawing, lay it out on the table, put all the pictures out there that I had, pictures of jobs. I'd give them my brochure, I'd give trade magazine articles that I'd written. I just would show off the work, period. I showed the work. That was my total way of doing it and I wrote about my projects.

But if we're talking about people who do struggle because they're not neurotypical, and they tend to be intelligent but society views them

I can't talk in abstractions. I'm a visual thinker, I only think in specific examples. Then I take specific examples and I put them into categories. Very verbalized, abstract things, I can only get specific examples of all right, here's a person where they had a successful career, here's a person that did not. What could have derailed their career?

I could talk about myself. This isn't so much in terms of derailing my career, but when I tell people I'm on the autism spectrum and that I struggle with mental health issues like ADD, anxiety, depression frequently they respond by saying "Well you're so very intelligent." It seems like there is a struggle in reconciling the fact that I'm bright with the fact that I have all of these mental health issues. I know other people who are also successful in their careers who have had similar reactions.

So my question is, it seems like there's a cultural tendency to assume that if you struggle with mental health issues or you're not neurotypical, that means you're not very bright. And if you are very bright, that means you're well adjusted.

Intelligence and creativity is associated with mental health issues. I'm right now reviewing some literature on visual thinking and I'm finding papers where right now I'm looking at a bunch of journal articles I looked up online about the ability to remember your past. People who get really bad PTSD, the past just comes back like pictures. Then you've got people that are highly verbal, it's easier for them to forget that bad things have happened to them in the past. Some of those visual thinkers, they're really creative. I've worked with them on equipment design. I worked with two guys that had 20 patents each. Yeah they had problems drinking, they had some problems. They ended up both on Prozac and that basically saved them from the gutter. One still has a very successful business. I have to be very vague about what they do, I cannot identify them, they're still alive, [one] still owns a very successful business. I know he has problems with drinking. It's mechanical, very clever mechanical engineering is what he did, what he does.

That's where I was going with my earlier question. There seem to be these cultural assumptions that are not borne out by the scientific data. There is something else I want to go into, which is you're talking about the different types. In your book, you discuss the different types of autistic brains, the different manifestations

Of thinkers, different thinkers. I'm right now reviewing literature on this, recent literature. It's very clear that you've got some people, now they're not looking at mental health here, they're just looking at more career stuff. Object visualizer, that would be me. Thinks in pictures, often ends up in the arts, industrial designs. Then you have the visual-spatial, or mathematical mind, thinks in patterns. Then you have people that totally think in words. I'm right now reviewing literature right now, new literature, stuff published since 2016 after I did"The Autistic Brain", that totally supports this idea that you've got some people ... They have people that are mixtures though, the intermediate.

The person who is a super good object visualizer is going to be crappy in math, not good at math and the more spatial way of looking at things, the more mathematical way of looking at things. There's getting to be good evidence. The object visualizer and visual-spatial, the skills sort of are antagonistic. You can't be super good at both. You can be intermediate at both. But the people that are super good at object visualizing, like they are horrible at the more abstract, schematic and mathematic way of visual spatial. I'm horrible on a thing called paper fold test. I flunked that. Just last night, I took a little mechanical aptitude test that was online. I had to speed through and I got seven out of 10 right. I'm pretty sure I know which ones I got wrong.

For me personally, I've always been very good at writing and I tend to absorb a lot of information. I can read a 500-page book in a few hours and remember all of the major facts within that book months and months later. So I guess what category of intelligence would I then be in?

Let me just ask you a question. I want you to think about cell phone towers. How do they come into your mind?

I imagine a large metal tower in the middle of the woods.

Is it a specific or general?

I just imagine the concept of the tower. I don't visualize it.

Yeah, the visual thinker starts naming them off. Now I'm thinking of it, there's one I go by that's next to a gas station. It's one of their best fake trees but it's still really fake looking. As I talk about it now I see it.

Yeah, I just imagine the concept of a tower.

I take specific examples of cell phone towers. Now there's another cell phone tower, it's actually the Hilton hotel and they now have them along the edge of the roof. I see. I've also seen them used as church steeples. I'll never forget when I asked, this is when I discovered that some people didn't think visually, I asked a speech therapist at an autism conference, think about a church steeple. She just got very vague pointy thing. I see it and I start naming them off. Visual thinkers just come up, just like it showed in the movie, like PowerPoint slides.

So for me, I just think of the concept, I don't think of specifics.

Well then you're more verbal. You're probably a lot more verbal.

How would you say cultural attitudes towards non-neurotypical personality types have changed over the last 40 to 50 year?

Well it has changed. I look back on the people I worked with, welders and designer. The people who have the 20 patents, neither one of those, one barely graduated from high school and the other one I think dropped out of high school. They couldn't do math but they've got 20 patents and their stuff is out being used in the industry. They were saved by welding class. One guy he just started making stuff and selling it at local trade shows. That grew into a big business. I worked with welders, I worked with a lot of people. If I tell you of people I worked with on my projects, I'm going to guess 20 percent of them would be considered neurodiverse today. But this is long before that term ever [became popularized]. 20 percent were either autistic, dyslexic, or ADHD. There was one guy, looking at him now, he was sound sensitive. I'll never forget the job where I was chipping the slag off of his welds and me tapping with the chipping hammer drove him just crazy. I didn't realize it. This was back in 1980.

See more here:
Interview with Temple Grandin: Autism, genetics and the steep price of being intelligent - Salon

Posted in Genetics | Comments Off on Interview with Temple Grandin: Autism, genetics and the steep price of being intelligent – Salon

Genetic genealogy companies Ancestry, 23andMe begin COVID-19 research – Detroit Free Press

Posted: June 1, 2020 at 6:47 pm

Ancestry and 23andMe offer direct-to-consumer DNA tests.(Photo: Reviewed.com/Jackson Ruckar)

It's a question that has vexed researchers from the beginning of the coronavirus outbreak: Why do some people get severely ill and die from COVID-19, while others have mild symptoms or none at all?

Now, scientists at two direct-to-consumer genealogy DNA companies hope to use the genomesthey've collected from millions of people over the years to see if they can find a genetic explanation toanswer that question.

Both 23andMe and Ancestry have launched COVID-19 studies, asking U.S. adult customers who've already submitted DNA samples to answer online questions about how the virus affected or didn't affect them.

"From the early days ... I think it was clear to all of us that some people were getting very, very sick when they were affected with coronavirus, and some people had hardly any symptoms at all," said Dr. Catherine Ball,chief scientific officer at Utah-based Ancestry."It turns out that there are plenty of people who have no symptoms. The spectrum of human response to the same pathogen is unusual.

"And even with a bunch of comorbidities and other problems, it's still remarkably divergent in different people, even if they have the same age and have the same overall health. And soto geneticists, that looks like there's a genetic factor in whether people become infected in the first placeor have serious or mild symptoms."

With 16 million people who've already spit in vials and sent them to Ancestryfor genetic testing to find blood relatives who might be closely or distantly related or learn how much of their DNA suggests their relatives came from Africa or Asia or were Native American or European, Ball said the companyknew it had a potentially useful data pool to tap for COVID-19 research.

"We clearly want to take the opportunity to unleash that power to be able to see if there are genetic signals, and be able to help researchers and people making drugs and therapeutics and vaccines dosmarter work faster," she said.

Dr. Catherine Ball, chief scientific officer for Utah-based Ancestry.(Photo: Ancestry)

Of those 16 million DNA customers through Ancestry, so far about 500,000people have already taken an online survey to participate in the company'scoronavirus research.

At 23andMe, principal scientist Adam Auton said the California-based company's COVID-19 genome-wide association study launched in April.

About 10 million of itsgenotype customers are eligible for the study, he said.Of them, about 80%have consented to participate in research, and600,000 customers have opted into the COVID-19 study.

"It is a really quite tremendous response to the study and I think shows that people really do want to try and contribute to help understand and fight this disease," said Auton.

Both Ancestry and 23andMeacknowledge that the bigger the sample size, the better their research will be.

"Never ask a scientisthow much data she needsbecause she always needs more," Ball said. "We're really hoping to get a minimum of a million respondentsbecause we need to have a decent number of people who have tested positive to give us a statistical signal."

So far, about9,000 people in 23andMe'sCOVID-19 study reported that theytested positive for coronavirus.

"That's a pretty substantial number," Auton said. "However, it's the nature of genetic studies that we really need very large numbers of people to be able to draw connections between the genetic information and people's health information."

A worker at 23andMe performs DNA testing on samples provided by customers.(Photo: 23andMe)

Since the pandemic began,about 1.6million people in the United States, a country of 330 million, have tested positive for COVID-19. As the virus continues to spread,and more people get coronavirus diagnoses, the companies suspect that the number of people who will go on to enroll in their studies also is likely to rise.

"We understand this is an evolving situation," Ball said. "And while we can't shelter in place forever, at some point, as we're opening up our cities and states, more people will start contracting the virus."

Anyone who may have already filled out anonline COVID-19 survey on Ancestry.com or 23andMe.com, saying they had not yet had the virus, can go back and revise their answers later to reflect that they've contracted it.

To expand its research of people who've had COVID-19 even more, Auton said 23andMeis now offering tomail a free DNA test kit to any U.S adult who was hospitalized with COVID-19, but has not yet submitted a DNA sample to the company.

"We are essentially asking if people have been hospitalized with COVID-19, and they have recovered, if they would like to participate inour research. They can come to our website and we'll offer them a free kit,"Auton said.

The contents of a 23andMe kit.(Photo: 23andMe)

"We're very much interested in trying to get the word out so that people to hear about this because really every data point is going to be pretty valuable."

23andMe has emailed customers in areas hardest hit so far in the pandemic including those in Michiganto let them know about its study, Auton said.

"The best thing that we can do to make a difference for COVID is to really publish the results that we find and make them available to the research and scientific communities," he said.

23andMe haspublishedmore than 150 studies in peer-reviewed scientific journals, "the majority of which come from collaboration with the broader academic and the scientific community," Auton said,since it launched in 2006with its direct-to-consumer DNA kit.

But the company ran afoul of the U.S. Food and Drug Administration in 2013, when the agency ordered 23andMeto halt the release of genetic health information to customers, saying the company had yet to prove its tests were"analytically or clinically validated."

After revamping, the company passed FDA muster in 2017, and got authorization tooffergenetic healthreports that outlinedrisk for 10conditions, including late-onset Alzheimers disease andParkinsons disease.

Ancestry is new to the health genetics business. It launched AncestryHealth in 2019, with the disclaimer that its tests are physician-ordered and not diagnostic, but offer "health insights" into whether a person might be a carrier for cystic fibrosis or sickle cell anemia or whether there's a genetic variant associated with a higher risk for breast cancer or colon cancer.

Ball said Ancestry also will seek to publish its COVID-19 research findings, too.

"We will be doing our very best to publish our findings as quickly as possible, and making them as useful to clinicians and other researchers as quickly as possible," she said.

Ancestry DNA(Photo: Melissa Rorech)

Both companies are looking for research partners for the coronavirus studies. Ancestry has had nibbles from universities, biotech and pharmaceutical companies, but Ball said, right now, the focus is on safeguarding the privacy of its customers.

"We typically do not share data out with third parties," Ball said. "That's an unusual activity for us.

"We will not be sharingpersonal data. Everything will be de-identified. So names, email addresses, your address, your ZIP code, your phone number, all that stuff will be stripped and will not be shared. We do want to still be very conservative because it is people's genetic data."

At 23andMe, individual-level data is never shared with a third party "without explicit additional consent from participants," Auton said.

"The information that we're talking about here, where we would be working with the academic community, is all aggregated at a very high level. So it's really just information about whether a specific genetic variant is associated with the disease. It doesn't contain any information about the individuals in the study."

Ball urged people to consider participating in this research for the common good.

"The people who came to AncestryDNA were interested in finding out about their ancestors, their past and their history," she said."This is our chancein this moment of history ... to take 5-10 minutes ... and do our best to help our community of friends or familyand the people who we don't even know who will be coming along later.

"It's our chance to contribute to the benefit of everybody. And I think right now, it'san opportunity that resonates with a lot of people."

Auton said the research could lead to therapies or treatments for people sickened by COVID-19.

"Hopefully, that can make a difference," he said.

Contact Kristen Jordan Shamus: 313-222-5997 or kshamus@freepress.com. Follow her on Twitter @kristenshamus.

Read or Share this story: https://www.freep.com/story/news/health/2020/05/26/genes-dna-ancestry-23-andme-coronavirus-covid-19/5223568002/

Read the original:
Genetic genealogy companies Ancestry, 23andMe begin COVID-19 research - Detroit Free Press

Posted in Genetics | Comments Off on Genetic genealogy companies Ancestry, 23andMe begin COVID-19 research – Detroit Free Press

Genetic features pave way for targeted BPDCN therapies – Dermatology Times

Posted: June 1, 2020 at 6:47 pm

Researchers are learning more about genetic aberrations common in the rare but clinically aggressive hematological cancer blastic plasmacytoid dendritic cell neoplasm. There is one targeted therapy approved by the U.S. Food and Drug Administration: Elzonris (tagraxofusp-erzs, Stemline). However, more treatment options are needed to improve the cancers clinical outcome, according to a review published May 2020 in Critical Reviews Oncology/Hematology.1

Dermatologists might be the first providers to encounter patients with blastic plasmacytoid dendritic cell neoplasm because more than 70% of these patients have cutaneous lesions. Those lesions often are asymptomatic and vary in size. The skin lesions tend to have nodules, plaques or bruise-like areas, a brown to violet color and might be solitary or multifocal, according to the authors.

Blastic plasmacytoid dendritic cell neoplasm often originates from type 2 myeloid-derived resting plasmacytoid dendritic cell precursors. Recent research suggests providers can diagnose the cancer when patients express at least four of five plasmacytoid dendritic cell specific markers, CD4, CD56, CD123, TCL1 and BDCA-2, without expressing myeloid, T-cell or B-cell lineage markers.

Commonly, [blastic plasmacytoid dendritic cell neoplasm] is characterized by high CD123 expression, aberrant NF-B [nuclear factor-B] activation, dependence on TCF4-/BRD4-network, and deregulated cholesterol metabolism, they wrote.

Despite advancing knowledge about the cancer type, patients median overall survival remains at 12 to 14 months, according to the paper. Conventional treatment approaches include chemotherapy, radiotherapy and ultimately hematopoietic stem cell transplantation. The challenges with conventional therapies are while blastic plasmacytoid dendritic cell neoplasm is sensitive to some chemotherapy regimens, patient relapse is high at more than 60%. And many patients with blastic plasmacytoid dendritic cell neoplasm are too old or frail to have intensive chemotherapy or hematopoietic stem cell transplantation, according to the authors.

Recently, the most attractive agent for [blastic plasmacytoid dendritic cell neoplasm] is tagraxofusp, which is composed of the catalytic and translocation domains of diphtheria toxin (DT) fused to interleukin-3 (IL-3), the authors wrote.

Blastic plasmacytoid dendritic cell neoplasm cells overexpress interleukin-3 receptor subunit alpha (IL3RA, also called CD123). Elzonris, or tagraxofusp-erzs, is a CD123-directed cytotoxin given intravenously, which is used to treat blastic plasmacytoid dendritic cell neoplasm in adults and in pediatric patients 2 years and older.

Researchers reported in a study of 47 blastic plasmacytoid dendritic cell neoplasm patients published in 2019 in the New England Journal of Medicine that tagraxofusp led to clinical responses in untreated and relapsed patients.2 The overall response rate with tagraxofusp was 90% and the primary outcome of complete response and clinical complete response was 72% among the previously untreated patients. Overall response was 67% in the previously treated patients. Serious adverse events including capillary leak syndrome, hepatic dysfunction and thrombocytopenia were common, according to the NEJM paper.

More targeted therapies are needed to treat blastic plasmacytoid dendritic cell neoplasm, but many potential therapeutic agents are not advancing to clinical trials, according to authors of the paper in Critical Reviews Oncology/Hematology.

Common blastic plasmacytoid dendritic cell neoplasm characteristics are genetically heterogeneous and provide valuable drug targets, according to the authors.

Apart from aberrant activation of NF-B signaling pathway, which is highly dependent on TCF4- and BRD4- transcriptional networks, cholesterol metabolism deregulation and CD123 expression, defects of DNA damage repair and mitosis are new, potential common features of the cancer. Corresponding therapies might be promising, the authors wrote.

Venetoclax, anti-CD123 CAR-T, XmAb14045 and IMGN632 are in clinical trials for blastic plasmacytoid dendritic cell neoplasm. But the authors noted that bortezomib, lenalidomide, 5-aza and pralatrexate could easily be pushed to the front line of the cancers treatment.

Disclosures:

The authors report no relevant disclosures.

References:

1. Zhang X, Sun J, Yang M, Wang L, Jin J. New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm. Crit Rev Oncol Hematol. 2020 May;149:102928.2. Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. N Engl J Med. 2019;380(17):1628-1637.

See the original post here:
Genetic features pave way for targeted BPDCN therapies - Dermatology Times

Posted in Genetics | Comments Off on Genetic features pave way for targeted BPDCN therapies – Dermatology Times

For cancer treatment and more, genetic-based precision medicine holds a lot of promise – Connecticut Magazine

Posted: June 1, 2020 at 6:47 pm

A month following surgery for thyroid cancer, a Hartford Hospital patients tumor grew to 10 inches. The case was presented to the hospitals tumor board, which involved 30 doctors from different specialties.

The gene mutation found to be controlling the patients tumor growth was already well-established as a driver of melanoma, the deadliest form of skin cancer, says Dr. Sope Olugbile, medical oncologist at Hartford HealthCare.Chemotherapy wouldnt work fast enough against the aggressive tumor. Tumor board members recommended a targeted therapy already treating patients with melanoma. Without that genetic information, we wouldnt have been able to come up with that therapy, he says. The treatment saved the patients life, so far. Our goal is to use more of the genetic information to drive the treatment of cancer patients.

This type of personalized care, known as precision medicine and its subset, genomic medicine, has been offered for years at world-renowned cancer-treatment hospitals such as Memorial Sloan Kettering Cancer Center in New York, Dana-Farber Cancer Institute in Boston and University of Texas MD Anderson Cancer Center in Houston. Its now the standard of care in Connecticuts Hartford HealthCare Cancer Institute, UConn Health Center in Farmington, Connecticut Childrens Medical Center in Hartford and Smilow Cancer Center at Yale New Haven Health.Cancer therapy has become precision therapy, says Dr. Roy Herbst, professor of medicinal oncology and pharmacology, and chief of medical oncology at Yale Cancer Center and Smilow Cancer Hospital.

Dr. Roy Herbst, of Yale Cancer Center and Smilow Cancer Hospital, says that precision care is often used in cancer treatment these days.

While its most commonly used with cancer patients, precision medicine is also making inroads into other areas of health care including the treatment of some cardiac patients. Its also being studied and used on a limited basis to treat those with rare diseases. In the U.S., newborns are screened with a blood test for hearing loss and heart defects. If detected and treated early, this can prevent death and disability in some cases. For some doctors and researchers, precision medicine holds the promise of effective targeted diseases and chronic conditions, and, even more revolutionary, the chance to prevent illness before it arises. The race is on to gather as much data as possible in order to increase understanding of the connection between genes and overall health; here in Connecticut, Yales Center for Genetic Health last fall launched its Generations project to collect DNA from 100,000 volunteers (see sidebar below).

Precision medicine involves the study of human genes, called the genome. The human genome contains 23 pairs of chromosomes within all human cells, and each chromosome contains hundreds to thousands of genes. Using high-level computing and mathematics, genomics researchers analyze massive amounts of DNA-sequence data to find variations or mutations that affect health, disease or response to drugs, according to an online description by The Jackson Laboratory for Genomic Medicine in Farmington.

Researchers can sequence an entire tumor to look for markers or abnormalities that can be treated with a targeted medication that attacks that mutation, unlike traditional chemotherapy that kills healthy cells along with cancer cells, says Herbst, also associate director for translational science at the Yale School of Medicine.

These days, when Yales precision medicine tumor board meets weekly, they dont focus on where the tumor began, he says. They look at what errors occurred in the DNA of the tumor, because once they know whats driving the tumor, they can treat it.For example, lung cancer is the most common cancer in the world. When a nonsmoker gets lung cancer, doctors sequence the tumors DNA to see if it contains one of eight genes known to mutate.

Each cancer cell has about 18,000 to 20,000 genes, and there are some cancers where just one of those genes is directing the growth of the cancer, Olugbile says. We call that the driver gene. The other 17,999 are just following the lead of that driver gene, he says. That means if we tag just that one gene with the medication then we can actually shut down the growth of the entire cancer.

Traditional chemotherapy can only be given for 4-6 months because of the side effects, while targeted oral medications have very few side effects and patients remain on them for an average of two years, Olugbile says.

In the past five years, genetic testing has become standard of care for some cancers specifically colon, lung and melanoma because those types of cancers tend to have genetic mutations that have been known to respond to therapy, says Sara Patterson, manager of clinical analytics and curation at Jackson Labs, which works with UConn and Yale researchers.But targeted therapy is not a cure-all, and researchers are still a long way from using precision medicine to treat all cancer patients. Even if cancers have the same genomic change and mutation, theres no guarantee they will all respond to the same therapy, she says.Overall, precision medicine is only effective at stopping the spread of cancer in an average of 20 percent of cancer patients treated, Olugbile says, with variations by cancer. Sometimes the cancer returns because the tumor changes to resist the therapy, Patterson adds.

As doctors and researchers do more genomic sequencing, the data pool will grow and so will knowledge of what medications work most effectively against various tumor types.The more information we gather, the better well know how to treat specific patients, Patterson says.

Reimbursement from insurance companies can be a challenge. If precision treatment for a particular type of cancer hasnt been approved by the insurance industry, its difficult to get reimbursed for genomic testing, says Sue Mockus, director of product innovation and strategic commercialization at Jackson Labs.Its a catch-22. Even though a patient with pancreatic cancer could benefit from a targeted therapy, unless that patient is part of a clinical trial that would pay for the genomic testing, the patient would have to pay out of pocket, the annual cost of which can run into the hundreds of thousands of dollars. If you do have a mutation identified and your physician wants to give you the medication off label, you have to fight with the insurance company, Mockus says.

Experts have suggested a value-based approach to precision medicine, reports the International Journal of Public Health. This means policy decisions about reimbursement and investment in research and development will factor in how long patients lives are prolonged and the quality of those lives, the Journal reports.

Oncologists also offer cancer patients immunotherapy, another form of personalized medicine, Patterson says. Theyre using diagnostic tests on tumors, independent of genomic sequencing, to determine if their tumor profiles make them a good immunotherapy candidate. Immunotherapy is approved for multiple tumor types, as long as they have certain markers, she says.

Former President Jimmy Carter became cancer free after receiving radiation and immunotherapy to treat the melanoma that had spread to his brain and liver. While immunotherapy can cure cancer for some, its only effective about 20 percent of the time, Olugbile says. It varies a bit by cancer, with some cancers having a higher success rate, he adds.

Through a collaboration with Memorial Sloan Kettering, Hartford HealthCares Advanced Disease Clinic was scheduled to open this spring to give patients even more options, he says. If targeted therapies and immunotherapies dont work or are not a match for patients, doctors will look for suitable clinical trials that offer potential treatments, Olugbile says.Our goal is to create awareness on two fronts, one is among the doctors. Yes, we are available to help if patients have gone through standard of care who didnt respond, he says. Its also an option for patients who want to be treated with precision medicine closer to home. The goal is to make it available so they dont have to go to New York or Boston, he says. Its right here in Hartford and hopefully at other cancer centers over time.

From Yale, Herbst leads a clinical trial through the National Cancer Institute where he and his team are trying to match the right patient to the right drug.Every tumor is getting sequenced. Thats accelerating the field. The sequencing techniques have gotten cheaper and faster, so we can analyze them at the point of care, Herbst says. This is why clinical trials are so important. Whats a clinical trial today is standard of care tomorrow.

In a study published in the journal Science Translational Medicine, a multi-institutional research team including a Connecticut doctor developed an advanced method to analyze existing data from thousands of clinical trials, comparing which genes FDA-approved drugs work against to the genes active in pediatric brain tumor patients. This sped up the lengthy process of developing cancer drugs.

Dr. Ching Lau, head of the oncology-hematology division at Connecticut Childrens Medical Center and the pediatric oncology-hematology department at UConn School of Medicine, is accessing the World Community Grid, an IBM-funded program that allows researchers worldwide to perform tens of thousands of virtual experiments. Instead of screening thousands and thousands of compounds to try to find a potential drug, we found we could use genomics data already available and do a more systems-approach analysis to figure out the predominant pathways driving the tumor cells, Lau, professor at The Jackson Laboratory, says in an email. Then we asked if there were any existing FDA-approved drugs that could potentially modulate those pathways.

The researchers identified eight drugs that could potentially fight medulloblastoma (MB) tumors, the most common malignant brain tumor in children. One of the drugs showed an increased survival rate in mice with MB tumors, and a clinical trial is being pursued.

Personalized medicineand heart disease

Precision medicines applications have expanded beyond cancer care. At first, much heart disease research relied on a genetic analysis of whether someone was predisposed to a disease. Thanks to a growing database of patient information that is shared worldwide, researchers can mine huge data sets with hundreds of thousands of cases for patterns and abnormalities that lead to discoveries, says Beth Taylor, associate professor of kinesiology at UConn and director of exercise physiology research in cardiology at Hartford Hospital. Researchers and clinicians know that about half the people who have heart attacks dont have the typical risk factors such as high blood pressure, obesity and diabetes. To determine why physically active people with healthy diets have heart attacks, researchers are using precision medicine to comb through large studies to find small predictors, Taylor says. Often the influence of any one factor is hard to detect unless you have a big sample size, she says.

The National Institutes of Health requires grant recipients to share their data to a national registry so that researchers have access to big data, she says. (Personal information such as date of birth, name and address are removed from files used for research studies.)

When we first began to really measure genetic variations, it was believed that was going to be the big hope in treatment, Taylor says. But genes are complex and environmental factors modify genetics for multiple generations.

For the first time ever, weve got wide-scale computing ability to analyze huge data points. This can better allow us to predict disease progression and optimize treatment, she says. Many of us would say that this concept of big data is as or more important than genetic risk. Genetic risks are not the whole picture.

For the first time ever, weve got wide-scale computing ability to analyze huge data points. This can better allow us to predict disease progression and optimize treatment.

Progress with diabetes

Precision medicine is not widely used in the treatment ofdiabetesin the U.S., except when it comes to a rare form of diabetes called neonatal diabetes mellitus. While type 1 and type 2 diabetes are controlled by two or more genesand additional genetic factors,neonatal diabetes mellitus involves a single gene and develops in babies under 6 months old.

Through genetic testing of babies with elevated blood sugar levels,researchers learnedthat about half the patients have gene mutations that respond well to a pill used to treat type 2 diabetes and they dont need to be on insulin for the rest of their lives like type 1 diabetics, says Karel Erion,director of research stewardship and communications for the American Diabetes Association.

When infants show signs of type 1 diabetes at Yale New Haven Childrens Hospital or Connecticut Childrens Medical Center, they are automatically tested for neonatal diabetes, hospital doctors say.

An example of precision medicine as a predictor of disease is the TrialNet database, which uses genetic testing to determine whether the relatives of those with type 1 diabetes have two or more of the five diabetes-related autoantibodies (proteins produced by the immune system directed against the persons own proteins) linked to increased risk of developing type 1 diabetes. Type 1 diabetics must take insulin for the rest of their lives to survive, and theres no known way to prevent the autoimmune disease. Type 1 diabetes, formerly called juvenile diabetes, typically strikes children and adolescents, causing the pancreas to stop producing insulin, a hormone needed to process sugar, or glucose, from food. Type 2 diabetes was formerly known as adult-onset diabetes, but the disorder is being seen in more children, thought to be the result of a rise in childhood obesity. Screening identifies the early stages of the disease years before any symptoms appear, according to the TrialNet website.

In a study published in the New England Journal of Medicine, researchers from the TrialNet Study Group, led by Yale Universitys Dr. Kevan Herold, found that an experimental medication delayed the onset of type 1 diabetes in high-risk participants by two years compared to the control group. The disease was diagnosed in 43 percent of the participants who received the medication, teplizumab, and 72 percent of those who received the placebo.

Alzheimers disease and dementia

Only 1 to 3 percent of the 5 million people living with Alzheimers disease have a genetic mutation that leads to whats called genetic or familial Alzheimers. But one in three older adults will eventually develop some form of dementia, says Rebecca Edelmayer, the Alzheimers Association director of scientific engagement.

Like other diseases that strike large segments of the population, researchers rely on big data to learn about Alzheimers and which genes play a role in who gets it.Researchers have learned that there are several risk factors that contribute to dementia, she says. Specifically, the presence of heart disease, high blood pressure, diabetes, social and cognitive isolation, poor nutrition and the level of education, can contribute to cognitive decline, she says.

Scientists from around the world share research data and draw from data in the Global Alzheimers Association Interactive Network, she says.The field has made some dramatic advances in understanding of how genetics play a role and how other underlying diseases play a role, Edelmayer says. We need to give doctors evidence-based recommendations.

Read the original here:
For cancer treatment and more, genetic-based precision medicine holds a lot of promise - Connecticut Magazine

Posted in Genetics | Comments Off on For cancer treatment and more, genetic-based precision medicine holds a lot of promise – Connecticut Magazine

Global Testosterone Replacement Therapy Market Business Outlook with COVID-19 Scenario -AbbVie, Upsher-Smith, Endo International, Pfizer, Actavis…

Posted: June 1, 2020 at 6:45 pm

Global Testosterone Replacement Therapy Market is an extensive compilation of in-depth analysis, factual assessments, value chain structure, industrial environment, regional analysis, applications, market size, share, and forecast. The report explains historic and current market status to provide comprehension for forthcoming occurrences in the market. The report provides an overall analysis of the market based on types, applications, regions, and the forecast period from 2020 to 2025. It also offers investment opportunities and probable threats in the market based on an intelligent analysis. The research will help you to depict the entire global Testosterone Replacement Therapy market through authentic and reliable estimation.

Our report highlights the major issues and hazards that companies might come across due to the unprecedented outbreak of COVID-19.

DOWNLOAD FREE SAMPLE: https://www.mrinsights.biz/report-detail/236403/request-sample

Competitive Landscape:

The report examines the global Testosterone Replacement Therapy market competition by focusing on leading industry players with information such as company profiles, components, and services offered, financial information of the past years, key developments in the previous years. The study presents the strengths and weaknesses of these companies and provides information about various strategies used by these players. The key strategies used by the leading players such as new products, innovation, expanding business through mergers, acquisitions, and partnerships are highlighted.

The most significant players coated in global Testosterone Replacement Therapy market report: AbbVie, Upsher-Smith, Endo International, Pfizer, Actavis (Allergan), Eli lilly, Teva, Bayer, Mylan, Novartis, Ferring Pharmaceuticals, Acerus Pharmaceuticals, Kyowa Kirin

Scope of The Market Report:

The report offers a forward-looking perspective on different factors driving or limiting the market growth. An exceptionally workable estimation of the present industry scenario has been delivered in the study, and the global Testosterone Replacement Therapy market size with regards to the revenue and volume have also been mentioned. In short, the report provides a detailed analysis of the global market size, regional and country-level market size, segment growth, market share, competitive landscape, sales analysis, the impact of domestic and global market players, value chain optimization, trade regulations, and recent developments in different regions.

The report offers an in-depth assessment of the growth and other aspects of the market in key countries including the

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Global Testosterone Replacement Therapy market by Type: Gels, Injections, Patches, Other

Global Testosterone Replacement Therapy market by application: Hospitals, Clinics, Other

READ FULL REPORT: https://www.mrinsights.biz/report/global-testosterone-replacement-therapy-market-growth-2020-2025-236403.html

The Listing Supplies Hints On The Upcoming Pointers:

Business Diversification: Market information about new services, untapped geographies, the latest advances, and also investments.

Assessment: In-depth investigation of plans, services, and manufacturing capabilities of these top players.

Business Intelligence: Comprehensive information on Testosterone Replacement Therapy made accessible the very active players in the global sector.

Product Development/Innovation: Comprehensive information about technology, R&D pursuits, together with brand new product launches out of the global Testosterone Replacement Therapy market.

Market Development: Comprehensive information regarding flourishing emerging markets in which the report assesses the market to get worldwide records

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs.

The rest is here:
Global Testosterone Replacement Therapy Market Business Outlook with COVID-19 Scenario -AbbVie, Upsher-Smith, Endo International, Pfizer, Actavis...

Posted in Testosterone Replacement Therapy | Comments Off on Global Testosterone Replacement Therapy Market Business Outlook with COVID-19 Scenario -AbbVie, Upsher-Smith, Endo International, Pfizer, Actavis…

Testosterone Replacement Therapy Market 2020 Analysis of Competitive Developments Such As Expansions, Agreements, New Product Launches, And…

Posted: June 1, 2020 at 6:45 pm

Latest Report On Testosterone Replacement Therapy Market including Market Landscape, and Market size, Revenues by players, Revenues by regions, Average prices, Competitive landscape, market Dynamics and industry trends and developments during the forecast period.

The global Testosterone Replacement Therapy market is broadly analyzed in this report that sheds light on critical aspects such as the vendor landscape, competitive strategies, market dynamics, and regional analysis. The report helps readers to clearly understand the current and future status of the global Testosterone Replacement Therapy market. The research study comes out as a compilation of useful guidelines for players to secure a position of strength in the global market. The authors of the report profile leading companies of the global Testosterone Replacement Therapy market, Also the details about important activities of leading players in the competitive landscape.

Key companies operating in the global Testosterone Replacement Therapy market include: , AbbVie, Endo International, Eli lilly, Pfizer, Actavis (Allergan), Bayer, Novartis, Teva, Mylan, Upsher-Smith, Ferring Pharmaceuticals, Kyowa Kirin, Acerus Pharmaceuticals

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1433485/global-testosterone-replacement-therapy-market

The report predicts the size of the global Testosterone Replacement Therapy market in terms of value and volume for the forecast period 2020-2026. As per the analysis provided in the report, the global Testosterone Replacement Therapy market is expected to rise at a CAGR of xx % between 2020 and 2026 to reach a valuation of US$ xx million/billion by the end of 2026. In 2020, the global Testosterone Replacement Therapy market attained a valuation of US$ XX million/billion. The market researchers deeply analyze the global Testosterone Replacement Therapy industry landscape and the future prospects it is anticipated to create

Segmental Analysis

The report has classified the global Testosterone Replacement Therapy industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Testosterone Replacement Therapy manufacturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Testosterone Replacement Therapy industry.

Global Testosterone Replacement Therapy Market Segment By Type:

, :, Gels, Injections, Patches, Other ,

Global Testosterone Replacement Therapy Market Segment By Application:

: Hospitals Clinics Others

Competitive Landscape

It is important for every market participant to be familiar with the competitive scenario in the global Testosterone Replacement Therapy industry. In order to fulfill the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key companies operating in the global Testosterone Replacement Therapy market include: , AbbVie, Endo International, Eli lilly, Pfizer, Actavis (Allergan), Bayer, Novartis, Teva, Mylan, Upsher-Smith, Ferring Pharmaceuticals, Kyowa Kirin, Acerus Pharmaceuticals

Key questions answered in the report:

Enquire for Customization in the Report: https://www.qyresearch.com/customize-request/form/1433485/global-testosterone-replacement-therapy-market

TOC

Table of Contents 1 Testosterone Replacement Therapy Market Overview1.1 Product Overview and Scope of Testosterone Replacement Therapy1.2 Testosterone Replacement Therapy Segment by Type1.2.1 Global Testosterone Replacement Therapy Sales Growth Rate Comparison by Type (2021-2026)1.2.2 Gels1.2.3 Injections1.2.4 Patches1.2.5 Other1.3 Testosterone Replacement Therapy Segment by Application1.3.1 Testosterone Replacement Therapy Sales Comparison by Application: 2020 VS 20261.3.2 Hospitals1.3.3 Clinics1.3.4 Others1.4 Global Testosterone Replacement Therapy Market Size Estimates and Forecasts1.4.1 Global Testosterone Replacement Therapy Revenue 2015-20261.4.2 Global Testosterone Replacement Therapy Sales 2015-20261.4.3 Testosterone Replacement Therapy Market Size by Region: 2020 Versus 2026 2 Global Testosterone Replacement Therapy Market Competition by Manufacturers2.1 Global Testosterone Replacement Therapy Sales Market Share by Manufacturers (2015-2020)2.2 Global Testosterone Replacement Therapy Revenue Share by Manufacturers (2015-2020)2.3 Global Testosterone Replacement Therapy Average Price by Manufacturers (2015-2020)2.4 Manufacturers Testosterone Replacement Therapy Manufacturing Sites, Area Served, Product Type2.5 Testosterone Replacement Therapy Market Competitive Situation and Trends2.5.1 Testosterone Replacement Therapy Market Concentration Rate2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)2.6 Manufacturers Mergers & Acquisitions, Expansion Plans2.7 Primary Interviews with Key Testosterone Replacement Therapy Players (Opinion Leaders) 3 Testosterone Replacement Therapy Retrospective Market Scenario by Region3.1 Global Testosterone Replacement Therapy Retrospective Market Scenario in Sales by Region: 2015-20203.2 Global Testosterone Replacement Therapy Retrospective Market Scenario in Revenue by Region: 2015-20203.3 North America Testosterone Replacement Therapy Market Facts & Figures by Country3.3.1 North America Testosterone Replacement Therapy Sales by Country3.3.2 North America Testosterone Replacement Therapy Sales by Country3.3.3 U.S.3.3.4 Canada3.4 Europe Testosterone Replacement Therapy Market Facts & Figures by Country3.4.1 Europe Testosterone Replacement Therapy Sales by Country3.4.2 Europe Testosterone Replacement Therapy Sales by Country3.4.3 Germany3.4.4 France3.4.5 U.K.3.4.6 Italy3.4.7 Russia3.5 Asia Pacific Testosterone Replacement Therapy Market Facts & Figures by Region3.5.1 Asia Pacific Testosterone Replacement Therapy Sales by Region3.5.2 Asia Pacific Testosterone Replacement Therapy Sales by Region3.5.3 China3.5.4 Japan3.5.5 South Korea3.5.6 India3.5.7 Australia3.5.8 Taiwan3.5.9 Indonesia3.5.10 Thailand3.5.11 Malaysia3.5.12 Philippines3.5.13 Vietnam3.6 Latin America Testosterone Replacement Therapy Market Facts & Figures by Country3.6.1 Latin America Testosterone Replacement Therapy Sales by Country3.6.2 Latin America Testosterone Replacement Therapy Sales by Country3.6.3 Mexico3.6.3 Brazil3.6.3 Argentina3.7 Middle East and Africa Testosterone Replacement Therapy Market Facts & Figures by Country3.7.1 Middle East and Africa Testosterone Replacement Therapy Sales by Country3.7.2 Middle East and Africa Testosterone Replacement Therapy Sales by Country3.7.3 Turkey3.7.4 Saudi Arabia3.7.5 U.A.E 4 Global Testosterone Replacement Therapy Historic Market Analysis by Type4.1 Global Testosterone Replacement Therapy Sales Market Share by Type (2015-2020)4.2 Global Testosterone Replacement Therapy Revenue Market Share by Type (2015-2020)4.3 Global Testosterone Replacement Therapy Price Market Share by Type (2015-2020)4.4 Global Testosterone Replacement Therapy Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Global Testosterone Replacement Therapy Historic Market Analysis by Application5.1 Global Testosterone Replacement Therapy Sales Market Share by Application (2015-2020)5.2 Global Testosterone Replacement Therapy Revenue Market Share by Application (2015-2020)5.3 Global Testosterone Replacement Therapy Price by Application (2015-2020) 6 Company Profiles and Key Figures in Testosterone Replacement Therapy Business6.1 AbbVie6.1.1 Corporation Information6.1.2 AbbVie Description, Business Overview and Total Revenue6.1.3 AbbVie Testosterone Replacement Therapy Sales, Revenue and Gross Margin (2015-2020)6.1.4 AbbVie Products Offered6.1.5 AbbVie Recent Development6.2 Endo International6.2.1 Endo International Testosterone Replacement Therapy Production Sites and Area Served6.2.2 Endo International Description, Business Overview and Total Revenue6.2.3 Endo International Testosterone Replacement Therapy Sales, Revenue and Gross Margin (2015-2020)6.2.4 Endo International Products Offered6.2.5 Endo International Recent Development6.3 Eli lilly6.3.1 Eli lilly Testosterone Replacement Therapy Production Sites and Area Served6.3.2 Eli lilly Description, Business Overview and Total Revenue6.3.3 Eli lilly Testosterone Replacement Therapy Sales, Revenue and Gross Margin (2015-2020)6.3.4 Eli lilly Products Offered6.3.5 Eli lilly Recent Development6.4 Pfizer6.4.1 Pfizer Testosterone Replacement Therapy Production Sites and Area Served6.4.2 Pfizer Description, Business Overview and Total Revenue6.4.3 Pfizer Testosterone Replacement Therapy Sales, Revenue and Gross Margin (2015-2020)6.4.4 Pfizer Products Offered6.4.5 Pfizer Recent Development6.5 Actavis (Allergan)6.5.1 Actavis (Allergan) Testosterone Replacement Therapy Production Sites and Area Served6.5.2 Actavis (Allergan) Description, Business Overview and Total Revenue6.5.3 Actavis (Allergan) Testosterone Replacement Therapy Sales, Revenue and Gross Margin (2015-2020)6.5.4 Actavis (Allergan) Products Offered6.5.5 Actavis (Allergan) Recent Development6.6 Bayer6.6.1 Bayer Testosterone Replacement Therapy Production Sites and Area Served6.6.2 Bayer Description, Business Overview and Total Revenue6.6.3 Bayer Testosterone Replacement Therapy Sales, Revenue and Gross Margin (2015-2020)6.6.4 Bayer Products Offered6.6.5 Bayer Recent Development6.7 Novartis6.6.1 Novartis Testosterone Replacement Therapy Production Sites and Area Served6.6.2 Novartis Description, Business Overview and Total Revenue6.6.3 Novartis Testosterone Replacement Therapy Sales, Revenue and Gross Margin (2015-2020)6.4.4 Novartis Products Offered6.7.5 Novartis Recent Development6.8 Teva6.8.1 Teva Testosterone Replacement Therapy Production Sites and Area Served6.8.2 Teva Description, Business Overview and Total Revenue6.8.3 Teva Testosterone Replacement Therapy Sales, Revenue and Gross Margin (2015-2020)6.8.4 Teva Products Offered6.8.5 Teva Recent Development6.9 Mylan6.9.1 Mylan Testosterone Replacement Therapy Production Sites and Area Served6.9.2 Mylan Description, Business Overview and Total Revenue6.9.3 Mylan Testosterone Replacement Therapy Sales, Revenue and Gross Margin (2015-2020)6.9.4 Mylan Products Offered6.9.5 Mylan Recent Development6.10 Upsher-Smith6.10.1 Upsher-Smith Testosterone Replacement Therapy Production Sites and Area Served6.10.2 Upsher-Smith Description, Business Overview and Total Revenue6.10.3 Upsher-Smith Testosterone Replacement Therapy Sales, Revenue and Gross Margin (2015-2020)6.10.4 Upsher-Smith Products Offered6.10.5 Upsher-Smith Recent Development6.11 Ferring Pharmaceuticals6.11.1 Ferring Pharmaceuticals Testosterone Replacement Therapy Production Sites and Area Served6.11.2 Ferring Pharmaceuticals Testosterone Replacement Therapy Description, Business Overview and Total Revenue6.11.3 Ferring Pharmaceuticals Testosterone Replacement Therapy Sales, Revenue and Gross Margin (2015-2020)6.11.4 Ferring Pharmaceuticals Products Offered6.11.5 Ferring Pharmaceuticals Recent Development6.12 Kyowa Kirin6.12.1 Kyowa Kirin Testosterone Replacement Therapy Production Sites and Area Served6.12.2 Kyowa Kirin Testosterone Replacement Therapy Description, Business Overview and Total Revenue6.12.3 Kyowa Kirin Testosterone Replacement Therapy Sales, Revenue and Gross Margin (2015-2020)6.12.4 Kyowa Kirin Products Offered6.12.5 Kyowa Kirin Recent Development6.13 Acerus Pharmaceuticals6.13.1 Acerus Pharmaceuticals Testosterone Replacement Therapy Production Sites and Area Served6.13.2 Acerus Pharmaceuticals Testosterone Replacement Therapy Description, Business Overview and Total Revenue6.13.3 Acerus Pharmaceuticals Testosterone Replacement Therapy Sales, Revenue and Gross Margin (2015-2020)6.13.4 Acerus Pharmaceuticals Products Offered6.13.5 Acerus Pharmaceuticals Recent Development 7 Testosterone Replacement Therapy Manufacturing Cost Analysis7.1 Testosterone Replacement Therapy Key Raw Materials Analysis7.1.1 Key Raw Materials7.1.2 Key Raw Materials Price Trend7.1.3 Key Suppliers of Raw Materials7.2 Proportion of Manufacturing Cost Structure7.3 Manufacturing Process Analysis of Testosterone Replacement Therapy7.4 Testosterone Replacement Therapy Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers8.1 Marketing Channel8.2 Testosterone Replacement Therapy Distributors List8.3 Testosterone Replacement Therapy Customers 9 Market Dynamics 9.1 Market Trends 9.2 Opportunities and Drivers 9.3 Challenges 9.4 Porters Five Forces Analysis 10 Global Market Forecast10.1 Global Testosterone Replacement Therapy Market Estimates and Projections by Type10.1.1 Global Forecasted Sales of Testosterone Replacement Therapy by Type (2021-2026)10.1.2 Global Forecasted Revenue of Testosterone Replacement Therapy by Type (2021-2026)10.2 Testosterone Replacement Therapy Market Estimates and Projections by Application10.2.1 Global Forecasted Sales of Testosterone Replacement Therapy by Application (2021-2026)10.2.2 Global Forecasted Revenue of Testosterone Replacement Therapy by Application (2021-2026)10.3 Testosterone Replacement Therapy Market Estimates and Projections by Region10.3.1 Global Forecasted Sales of Testosterone Replacement Therapy by Region (2021-2026)10.3.2 Global Forecasted Revenue of Testosterone Replacement Therapy by Region (2021-2026)10.4 North America Testosterone Replacement Therapy Estimates and Projections (2021-2026)10.5 Europe Testosterone Replacement Therapy Estimates and Projections (2021-2026)10.6 Asia Pacific Testosterone Replacement Therapy Estimates and Projections (2021-2026)10.7 Latin America Testosterone Replacement Therapy Estimates and Projections (2021-2026)10.8 Middle East and Africa Testosterone Replacement Therapy Estimates and Projections (2021-2026) 11 Research Finding and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 Disclaimer

About Us

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from a huge number of customer supports, the QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in the consulting industry.

See original here:
Testosterone Replacement Therapy Market 2020 Analysis of Competitive Developments Such As Expansions, Agreements, New Product Launches, And...

Posted in Testosterone Replacement Therapy | Comments Off on Testosterone Replacement Therapy Market 2020 Analysis of Competitive Developments Such As Expansions, Agreements, New Product Launches, And…

Hormone Replacement Therapy Market 2020 Share Growing Rapidly With Latest Trends, Development, Revenue, Demand And Forecast To 2029 – WaterCloud News

Posted: June 1, 2020 at 6:45 pm

The research study on Global Hormone Replacement Therapy market 2019 presents an extensive analysis of current Hormone Replacement Therapy market size, drivers, trends, opportunities, challenges, as well as key Hormone Replacement Therapy market segments. Further, it explains various definitions and classification of the Hormone Replacement Therapy industry, applications, and chain structure.In continuation of this data, the Hormone Replacement Therapy report covers various marketing strategies followed by key players and distributors. Also explains Hormone Replacement Therapy marketing channels, potential buyers and development history. The intent of global Hormone Replacement Therapy research report is to depict the information to the user regarding Hormone Replacement Therapy market forecast and dynamics for the upcoming years. The Hormone Replacement Therapy study lists the essential elements which influence the growth of Hormone Replacement Therapy industry. Long-term evaluation of the worldwide Hormone Replacement Therapy market share from diverse countries and regions is roofed within the Hormone Replacement Therapy report. Additionally, includes Hormone Replacement Therapy type wise and application wise consumption figures.

The Final Report will cover the impact analysis of COVID-19 on this industry.

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10225607

After the basic information, the global Hormone Replacement Therapy Market study sheds light on the Hormone Replacement Therapy technological evolution, tie-ups, acquisition, innovative Hormone Replacement Therapy business approach, new launches and Hormone Replacement Therapy revenue. In addition, the Hormone Replacement Therapy industry growth in distinct regions and Hormone Replacement Therapy R;D status are enclosed within the report.The Hormone Replacement Therapy study also incorporates new investment feasibility analysis of Hormone Replacement Therapy. Together with strategically analyzing the key micro markets, the report also focuses on industry-specific drivers, restraints, opportunities, and challenges in the Hormone Replacement Therapy market.

View Source of RelatedReports :

Hormone Replacement Therapy Market

Natural Killer (NK) Cell Therapeutics Market

Genomics Market

Bioinformatics Market

Pharmacogenomics Market

Global Hormone Replacement Therapy Market Segmentation 2019: Hormone Replacement TherapyThe study also classifies the entire Hormone Replacement Therapy market on basis of leading manufacturers, different types, various applications and diverse geographical regions. Overall Hormone Replacement Therapy market is characterized by the existence of well-known global and regional Hormone Replacement Therapy vendors. These established Hormone Replacement Therapy players have huge essential resources and funds for Hormone Replacement Therapy research as well as developmental activities. Also, the Hormone Replacement Therapy manufacturers focusing on the development of new Hormone Replacement Therapy technologies and feedstock. In fact, this will enhance the competitive scenario of the Hormone Replacement Therapy industry.

The Leading Players involved in global Hormone Replacement Therapy market are:

By Therapy Type (Human Growth Hormone (HGH) Replacement Therapy, Testosterone Replacement Therapy, Thyroid Replacement Therapy, Estrogen Replacement Therapy)

By Application (Growth Hormone Deficiency,Menopause, Hypothyroidism, Male Hypogonadism, and Others)

By Route of Administration (Oral, Parenteral, and Others)

By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) 

By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa )

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10225607

Worldwide Hormone Replacement Therapy Market Different Analysis:Competitors Review of Hormone Replacement Therapy Market: Report presents the competitive landscape scenario seen among top Hormone Replacement Therapy players, their company profile, revenue, sales, business tactics and forecast Hormone Replacement Therapy industry situations. Production Review of Hormone Replacement Therapy Market: It illustrates the production volume, capacity with respect to major Hormone Replacement Therapy regions, application, type, and the price. Sales Margin and Revenue Accumulation Review of Hormone Replacement Therapy Market: Eventually explains sales margin and revenue accumulation based on key regions, price, revenue, and Hormone Replacement Therapy target consumer. Supply and Demand Review of Hormone Replacement Therapy Market: Coupled with sales margin, the report depicts the supply and demand seen in major regions, among key players and for every Hormone Replacement Therapy product type. Also interprets the Hormone Replacement Therapy import/export scenario. Other key reviews of Hormone Replacement Therapy Market: Apart from the above information, correspondingly covers the company website, number of employees, contact details of major Hormone Replacement Therapy players, potential consumers and suppliers. Also, the strengths, opportunities, Hormone Replacement Therapy market driving forces and market restraints are studied in this report.

Highlights of Global Hormone Replacement Therapy Market Report:* This report provides in detail analysis of the Hormone Replacement Therapy and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2019 ; 2029. * It also elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for world Hormone Replacement Therapy market. * This study also provides key insights about Hormone Replacement Therapy market drivers, restraints, opportunities, new product launches, approvals, regional outlook, and competitive strategies adopted by the leading Hormone Replacement Therapy players. * It profiles leading players in the worldwide Hormone Replacement Therapy market based on the following parameters ; company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans. * Insights from Hormone Replacement Therapy report would allow marketers and management authorities of companies to make an informed decision with respect to their future product launches, market expansion, and Hormone Replacement Therapy marketing tactics. * The world Hormone Replacement Therapy industry report caters to various stakeholders in Hormone Replacement Therapy market. That includes investors, device manufacturers, distributors and suppliers for Hormone Replacement Therapy equipment. Especially incorporates government organizations, Hormone Replacement Therapy research and consulting firms, new entrants, and financial analysts. *Various strategy matrices used in analyzing the Hormone Replacement Therapy market would provide stakeholders vital inputs to make strategic decisions accordingly.

Global Hormone Replacement Therapy Market Report Provides Comprehensive Analysis of Following: ; Hormone Replacement Therapy Market segments and sub-segments ; Industry size ; Hormone Replacement Therapy shares ; Hormone Replacement Therapy Market trends and dynamics ; Market Drivers and Hormone Replacement Therapy Opportunities ; Supply and demand of world Hormone Replacement Therapy industry ; Technological inventions in Hormone Replacement Therapy trade ; Hormone Replacement Therapy Marketing Channel Development Trend ; Global Hormone Replacement Therapy Industry Positioning ; Pricing and Brand Strategy ; Distributors/Traders List enclosed in Positioning Hormone Replacement Therapy Market.

Request For Full Report:https://www.kennethresearch.com/sample-request-10225607

Moreover, the report organizes to provide essential information on current and future Hormone Replacement Therapy market movements, organizational needs and Hormone Replacement Therapy industrial innovations. Additionally, the complete Hormone Replacement Therapy report helps the new aspirants to inspect the forthcoming opportunities in the Hormone Replacement Therapy industry. Investors will get a clear idea of the dominant Hormone Replacement Therapy players and their future forecasts.

About Kenneth Research:

Kenneth Research provides market research reports to different individuals, industries, associations and organizations with an aim of helping them to take prominent decisions. Our research library comprises of more than 10,000 research reports provided by more than 15 market research publishers across different industries. Our collection of market research solutions covers both macro level as well as micro level categories with relevant and suitable market research titles. As a global market research reselling firm, Kenneth Research provides significant analysis on various markets with pure business intelligence and consulting services on different industries across the globe. In addition to that, our internal research team always keep a track on the international and domestic market for any economic changes impacting the products demand, growth and opportunities for new and existing players.

Contact Us

Kenneth ResearchEmail: [emailprotected]Phone: +1 313 462 0609

The rest is here:
Hormone Replacement Therapy Market 2020 Share Growing Rapidly With Latest Trends, Development, Revenue, Demand And Forecast To 2029 - WaterCloud News

Posted in Testosterone Replacement Therapy | Comments Off on Hormone Replacement Therapy Market 2020 Share Growing Rapidly With Latest Trends, Development, Revenue, Demand And Forecast To 2029 – WaterCloud News

Hormone Replacement Therapy Market Study 2020-2026 by Current and Upcoming Trends, Opportunities, Size, Trends and Forecast – Weekly Wall

Posted: June 1, 2020 at 6:45 pm

Los Angeles, United State: Complete study of the global Hormone Replacement Therapy market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Hormone Replacement Therapy industry. Research techniques like PESTLE and Porters Five Forces analysis have been deployed by the researchers. They have also provided accurate data on Hormone Replacement Therapy production, capacity, price, cost, margin, and revenue to help the players gain a clear understanding into the overall existing and future market situation.

The research study includes great insights about critical market dynamics, including drivers, restraints, trends, and opportunities. It also includes various types of market analysis such as competitive analysis, manufacturing cost analysis, manufacturing process analysis, price analysis, and analysis of market influence factors. It is a complete study on the global Hormone Replacement Therapy market that can be used as a set of effective guidelines for ensuring strong growth in the coming years. It caters to all types of interested parties, viz. stakeholders, market participants, investors, market researchers, and other individuals associated with the Hormone Replacement Therapy business.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart)https://www.qyresearch.com/sample-form/form/1706851/covid-19-impact-on-global-hormone-replacement-therapy-market

It is important for every market participant to be familiar with the competitive scenario in the global Hormone Replacement Therapy industry. In order to fulfil the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key Players Mentioned in the Global Hormone Replacement Therapy Market Research Report: , Eli Lilly, Pfizer, AbbVie, Novo Nordisk, Merck KGaA, Mylan, Bayer, Teva, Novartis, Abbott, Roche, Endo International, Ipsen, ANI Pharmaceuticals, TherapeuticsMD Hormone Replacement Therapy

Global Hormone Replacement Therapy Market Segmentation by Product:, Estrogen Hormone, Growth Hormone, Thyroid Hormone, Testosterone Hormone, The proportion of estrogen hormone in 2018 is about 50%, and the proportion is in increasing trend from 2014 to 2018. Hormone Replacement Therapy

Global Hormone Replacement Therapy Market Segmentation by Application: Menopause, Hypothyroidism, Growth Hormone Deficiency, Male Hypogonadism, Other Diseases

The report has classified the global Hormone Replacement Therapy industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Hormone Replacement Therapy manufcaturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Hormone Replacement Therapy industry.

Additionally, the industry analysts have studied key regions including North America, Europe, Asia Pacific, Latin America, and Middle East and Africa, along with their respective countries. Here, they have given a clear-cut understanding of the present and future situations of the global Hormone Replacement Therapy industry in key regions. This will help the key players to focus on the lucrative regional markets.

Key questions answered in the report:

Request for customization in Report:https://www.qyresearch.com/customize-request/form/1706851/covid-19-impact-on-global-hormone-replacement-therapy-market

Table od Content

1 Study Coverage1.1 Hormone Replacement Therapy Product Introduction1.2 Market Segments1.3 Key Hormone Replacement Therapy Manufacturers Covered: Ranking by Revenue1.4 Market by Type1.4.1 Global Hormone Replacement Therapy Market Size Growth Rate by Type1.4.2 Estrogen Hormone1.4.3 Growth Hormone1.4.4 Thyroid Hormone1.4.5 Testosterone Hormone1.5 Market by Application1.5.1 Global Hormone Replacement Therapy Market Size Growth Rate by Application1.5.2 Menopause1.5.3 Hypothyroidism1.5.4 Growth Hormone Deficiency1.5.5 Male Hypogonadism1.5.6 Other Diseases1.6 Coronavirus Disease 2019 (Covid-19): Hormone Replacement Therapy Industry Impact1.6.1 How the Covid-19 is Affecting the Hormone Replacement Therapy Industry1.6.1.1 Hormone Replacement Therapy Business Impact Assessment Covid-191.6.1.2 Supply Chain Challenges1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products1.6.2 Market Trends and Hormone Replacement Therapy Potential Opportunities in the COVID-19 Landscape1.6.3 Measures / Proposal against Covid-191.6.3.1 Government Measures to Combat Covid-19 Impact1.6.3.2 Proposal for Hormone Replacement Therapy Players to Combat Covid-19 Impact1.7 Study Objectives1.8 Years Considered 2 Executive Summary2.1 Global Hormone Replacement Therapy Market Size Estimates and Forecasts2.1.1 Global Hormone Replacement Therapy Revenue 2015-20262.1.2 Global Hormone Replacement Therapy Sales 2015-20262.2 Hormone Replacement Therapy Market Size by Region: 2020 Versus 20262.2.1 Global Hormone Replacement Therapy Retrospective Market Scenario in Sales by Region: 2015-20202.2.2 Global Hormone Replacement Therapy Retrospective Market Scenario in Revenue by Region: 2015-2020 3 Global Hormone Replacement Therapy Competitor Landscape by Players3.1 Hormone Replacement Therapy Sales by Manufacturers3.1.1 Hormone Replacement Therapy Sales by Manufacturers (2015-2020)3.1.2 Hormone Replacement Therapy Sales Market Share by Manufacturers (2015-2020)3.2 Hormone Replacement Therapy Revenue by Manufacturers3.2.1 Hormone Replacement Therapy Revenue by Manufacturers (2015-2020)3.2.2 Hormone Replacement Therapy Revenue Share by Manufacturers (2015-2020)3.2.3 Global Hormone Replacement Therapy Market Concentration Ratio (CR5 and HHI) (2015-2020)3.2.4 Global Top 10 and Top 5 Companies by Hormone Replacement Therapy Revenue in 20193.2.5 Global Hormone Replacement Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 Hormone Replacement Therapy Price by Manufacturers3.4 Hormone Replacement Therapy Manufacturing Base Distribution, Product Types3.4.1 Hormone Replacement Therapy Manufacturers Manufacturing Base Distribution, Headquarters3.4.2 Manufacturers Hormone Replacement Therapy Product Type3.4.3 Date of International Manufacturers Enter into Hormone Replacement Therapy Market3.5 Manufacturers Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global Hormone Replacement Therapy Market Size by Type (2015-2020)4.1.1 Global Hormone Replacement Therapy Sales by Type (2015-2020)4.1.2 Global Hormone Replacement Therapy Revenue by Type (2015-2020)4.1.3 Hormone Replacement Therapy Average Selling Price (ASP) by Type (2015-2026)4.2 Global Hormone Replacement Therapy Market Size Forecast by Type (2021-2026)4.2.1 Global Hormone Replacement Therapy Sales Forecast by Type (2021-2026)4.2.2 Global Hormone Replacement Therapy Revenue Forecast by Type (2021-2026)4.2.3 Hormone Replacement Therapy Average Selling Price (ASP) Forecast by Type (2021-2026)4.3 Global Hormone Replacement Therapy Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Breakdown Data by Application (2015-2026)5.1 Global Hormone Replacement Therapy Market Size by Application (2015-2020)5.1.1 Global Hormone Replacement Therapy Sales by Application (2015-2020)5.1.2 Global Hormone Replacement Therapy Revenue by Application (2015-2020)5.1.3 Hormone Replacement Therapy Price by Application (2015-2020)5.2 Hormone Replacement Therapy Market Size Forecast by Application (2021-2026)5.2.1 Global Hormone Replacement Therapy Sales Forecast by Application (2021-2026)5.2.2 Global Hormone Replacement Therapy Revenue Forecast by Application (2021-2026)5.2.3 Global Hormone Replacement Therapy Price Forecast by Application (2021-2026) 6 North America6.1 North America Hormone Replacement Therapy by Country6.1.1 North America Hormone Replacement Therapy Sales by Country6.1.2 North America Hormone Replacement Therapy Revenue by Country6.1.3 U.S.6.1.4 Canada6.2 North America Hormone Replacement Therapy Market Facts & Figures by Type6.3 North America Hormone Replacement Therapy Market Facts & Figures by Application 7 Europe7.1 Europe Hormone Replacement Therapy by Country7.1.1 Europe Hormone Replacement Therapy Sales by Country7.1.2 Europe Hormone Replacement Therapy Revenue by Country7.1.3 Germany7.1.4 France7.1.5 U.K.7.1.6 Italy7.1.7 Russia7.2 Europe Hormone Replacement Therapy Market Facts & Figures by Type7.3 Europe Hormone Replacement Therapy Market Facts & Figures by Application 8 Asia Pacific8.1 Asia Pacific Hormone Replacement Therapy by Region8.1.1 Asia Pacific Hormone Replacement Therapy Sales by Region8.1.2 Asia Pacific Hormone Replacement Therapy Revenue by Region8.1.3 China8.1.4 Japan8.1.5 South Korea8.1.6 India8.1.7 Australia8.1.8 Taiwan8.1.9 Indonesia8.1.10 Thailand8.1.11 Malaysia8.1.12 Philippines8.1.13 Vietnam8.2 Asia Pacific Hormone Replacement Therapy Market Facts & Figures by Type8.3 Asia Pacific Hormone Replacement Therapy Market Facts & Figures by Application 9 Latin America9.1 Latin America Hormone Replacement Therapy by Country9.1.1 Latin America Hormone Replacement Therapy Sales by Country9.1.2 Latin America Hormone Replacement Therapy Revenue by Country9.1.3 Mexico9.1.4 Brazil9.1.5 Argentina9.2 Central & South America Hormone Replacement Therapy Market Facts & Figures by Type9.3 Central & South America Hormone Replacement Therapy Market Facts & Figures by Application 10 Middle East and Africa10.1 Middle East and Africa Hormone Replacement Therapy by Country10.1.1 Middle East and Africa Hormone Replacement Therapy Sales by Country10.1.2 Middle East and Africa Hormone Replacement Therapy Revenue by Country10.1.3 Turkey10.1.4 Saudi Arabia10.1.5 UAE10.2 Middle East and Africa Hormone Replacement Therapy Market Facts & Figures by Type10.3 Middle East and Africa Hormone Replacement Therapy Market Facts & Figures by Application 11 Company Profiles11.1 Eli Lilly11.1.1 Eli Lilly Corporation Information11.1.2 Eli Lilly Description, Business Overview and Total Revenue11.1.3 Eli Lilly Sales, Revenue and Gross Margin (2015-2020)11.1.4 Eli Lilly Hormone Replacement Therapy Products Offered11.1.5 Eli Lilly Recent Development11.2 Pfizer11.2.1 Pfizer Corporation Information11.2.2 Pfizer Description, Business Overview and Total Revenue11.2.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)11.2.4 Pfizer Hormone Replacement Therapy Products Offered11.2.5 Pfizer Recent Development11.3 AbbVie11.3.1 AbbVie Corporation Information11.3.2 AbbVie Description, Business Overview and Total Revenue11.3.3 AbbVie Sales, Revenue and Gross Margin (2015-2020)11.3.4 AbbVie Hormone Replacement Therapy Products Offered11.3.5 AbbVie Recent Development11.4 Novo Nordisk11.4.1 Novo Nordisk Corporation Information11.4.2 Novo Nordisk Description, Business Overview and Total Revenue11.4.3 Novo Nordisk Sales, Revenue and Gross Margin (2015-2020)11.4.4 Novo Nordisk Hormone Replacement Therapy Products Offered11.4.5 Novo Nordisk Recent Development11.5 Merck KGaA11.5.1 Merck KGaA Corporation Information11.5.2 Merck KGaA Description, Business Overview and Total Revenue11.5.3 Merck KGaA Sales, Revenue and Gross Margin (2015-2020)11.5.4 Merck KGaA Hormone Replacement Therapy Products Offered11.5.5 Merck KGaA Recent Development11.6 Mylan11.6.1 Mylan Corporation Information11.6.2 Mylan Description, Business Overview and Total Revenue11.6.3 Mylan Sales, Revenue and Gross Margin (2015-2020)11.6.4 Mylan Hormone Replacement Therapy Products Offered11.6.5 Mylan Recent Development11.7 Bayer11.7.1 Bayer Corporation Information11.7.2 Bayer Description, Business Overview and Total Revenue11.7.3 Bayer Sales, Revenue and Gross Margin (2015-2020)11.7.4 Bayer Hormone Replacement Therapy Products Offered11.7.5 Bayer Recent Development11.8 Teva11.8.1 Teva Corporation Information11.8.2 Teva Description, Business Overview and Total Revenue11.8.3 Teva Sales, Revenue and Gross Margin (2015-2020)11.8.4 Teva Hormone Replacement Therapy Products Offered11.8.5 Teva Recent Development11.9 Novartis11.9.1 Novartis Corporation Information11.9.2 Novartis Description, Business Overview and Total Revenue11.9.3 Novartis Sales, Revenue and Gross Margin (2015-2020)11.9.4 Novartis Hormone Replacement Therapy Products Offered11.9.5 Novartis Recent Development11.10 Abbott11.10.1 Abbott Corporation Information11.10.2 Abbott Description, Business Overview and Total Revenue11.10.3 Abbott Sales, Revenue and Gross Margin (2015-2020)11.10.4 Abbott Hormone Replacement Therapy Products Offered11.10.5 Abbott Recent Development11.1 Eli Lilly11.1.1 Eli Lilly Corporation Information11.1.2 Eli Lilly Description, Business Overview and Total Revenue11.1.3 Eli Lilly Sales, Revenue and Gross Margin (2015-2020)11.1.4 Eli Lilly Hormone Replacement Therapy Products Offered11.1.5 Eli Lilly Recent Development11.12 Endo International11.12.1 Endo International Corporation Information11.12.2 Endo International Description, Business Overview and Total Revenue11.12.3 Endo International Sales, Revenue and Gross Margin (2015-2020)11.12.4 Endo International Products Offered11.12.5 Endo International Recent Development11.13 Ipsen11.13.1 Ipsen Corporation Information11.13.2 Ipsen Description, Business Overview and Total Revenue11.13.3 Ipsen Sales, Revenue and Gross Margin (2015-2020)11.13.4 Ipsen Products Offered11.13.5 Ipsen Recent Development11.14 ANI Pharmaceuticals11.14.1 ANI Pharmaceuticals Corporation Information11.14.2 ANI Pharmaceuticals Description, Business Overview and Total Revenue11.14.3 ANI Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)11.14.4 ANI Pharmaceuticals Products Offered11.14.5 ANI Pharmaceuticals Recent Development11.15 TherapeuticsMD11.15.1 TherapeuticsMD Corporation Information11.15.2 TherapeuticsMD Description, Business Overview and Total Revenue11.15.3 TherapeuticsMD Sales, Revenue and Gross Margin (2015-2020)11.15.4 TherapeuticsMD Products Offered11.15.5 TherapeuticsMD Recent Development 12 Future Forecast by Regions (Countries) (2021-2026)12.1 Hormone Replacement Therapy Market Estimates and Projections by Region12.1.1 Global Hormone Replacement Therapy Sales Forecast by Regions 2021-202612.1.2 Global Hormone Replacement Therapy Revenue Forecast by Regions 2021-202612.2 North America Hormone Replacement Therapy Market Size Forecast (2021-2026)12.2.1 North America: Hormone Replacement Therapy Sales Forecast (2021-2026)12.2.2 North America: Hormone Replacement Therapy Revenue Forecast (2021-2026)12.2.3 North America: Hormone Replacement Therapy Market Size Forecast by Country (2021-2026)12.3 Europe Hormone Replacement Therapy Market Size Forecast (2021-2026)12.3.1 Europe: Hormone Replacement Therapy Sales Forecast (2021-2026)12.3.2 Europe: Hormone Replacement Therapy Revenue Forecast (2021-2026)12.3.3 Europe: Hormone Replacement Therapy Market Size Forecast by Country (2021-2026)12.4 Asia Pacific Hormone Replacement Therapy Market Size Forecast (2021-2026)12.4.1 Asia Pacific: Hormone Replacement Therapy Sales Forecast (2021-2026)12.4.2 Asia Pacific: Hormone Replacement Therapy Revenue Forecast (2021-2026)12.4.3 Asia Pacific: Hormone Replacement Therapy Market Size Forecast by Region (2021-2026)12.5 Latin America Hormone Replacement Therapy Market Size Forecast (2021-2026)12.5.1 Latin America: Hormone Replacement Therapy Sales Forecast (2021-2026)12.5.2 Latin America: Hormone Replacement Therapy Revenue Forecast (2021-2026)12.5.3 Latin America: Hormone Replacement Therapy Market Size Forecast by Country (2021-2026)12.6 Middle East and Africa Hormone Replacement Therapy Market Size Forecast (2021-2026)12.6.1 Middle East and Africa: Hormone Replacement Therapy Sales Forecast (2021-2026)12.6.2 Middle East and Africa: Hormone Replacement Therapy Revenue Forecast (2021-2026)12.6.3 Middle East and Africa: Hormone Replacement Therapy Market Size Forecast by Country (2021-2026) 13 Market Opportunities, Challenges, Risks and Influences Factors Analysis13.1 Market Opportunities and Drivers13.2 Market Challenges13.3 Market Risks/Restraints13.4 Porters Five Forces Analysis13.5 Primary Interviews with Key Hormone Replacement Therapy Players (Opinion Leaders) 14 Value Chain and Sales Channels Analysis14.1 Value Chain Analysis14.2 Hormone Replacement Therapy Customers14.3 Sales Channels Analysis14.3.1 Sales Channels14.3.2 Distributors 15 Research Findings and Conclusion 16 Appendix16.1 Research Methodology16.1.1 Methodology/Research Approach16.1.2 Data Source16.2 Author Details

About Us:

QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), experts resources (included energy automotive chemical medical ICT consumer goods etc.

Go here to see the original:
Hormone Replacement Therapy Market Study 2020-2026 by Current and Upcoming Trends, Opportunities, Size, Trends and Forecast - Weekly Wall

Posted in Testosterone Replacement Therapy | Comments Off on Hormone Replacement Therapy Market Study 2020-2026 by Current and Upcoming Trends, Opportunities, Size, Trends and Forecast – Weekly Wall

How safe are Ohio summer fun activities amid the coronavirus threat? The Wake Up for Friday, May 29, 2020 – cleveland.com

Posted: May 31, 2020 at 2:46 pm

Subscribe to the Wake Up, cleveland.coms free morning newsletter, delivered to your inbox weekdays at 5:30 a.m.

Today's Wake Up newsletter is longer than usual because it includes every coronavirus story from the last 24 hours. Read it and you're up to date on the crisis.

Today will be breezy, with showers and chances of thunderstorms. Highs will be in the upper 70s. The weekend will be mostly sunny but cool: Saturdays high will be around 66, and Sunday will be around 62. Read more.

Ranking risk: Summer this year means rating the risks of our favorite fun activities because of the coronavirus. Emily Bamforth and Mary Kilpatrick interviewed experts to assess the risk of that backyard barbecue or trip to the beach. While risk depends on how much space people have and whether others are wearing masks, doctors say kayaking as a family is safer than sending your kid to day camp, and camping is safer than renting a cabin. See the full list of activities.

Assisted living visitation: Gov. Mike DeWine said Thursday that the state would begin allowing limited visitation to some congregate-living facilities, Seth Richardson reports. Beginning June 8, assisted living facilities and homes for the developmentally disabled can resume outdoor visitation. Restrictions will be in place, including social distancing requirements, temperature screening for visitors and residents, mask-wearing and set hours.

Subtext: Cleveland.com has started a new, free Subtext account to send coronavirus updates. Every day, the team covering the coronavirus will send three to four updates about the progress of the virus -- confirmed cases of the virus, major cancellations, the latest medical advice, relevant scientific information and more. You can even text us back. Go to https://joinsubtext.com/ohiocoronavirus and enter your phone number. Fill out the form below. Or send a text to 216-279-7784. Did we mention its free?

This Week in the CLE: Ohio amusement parks, museums, zoos and other tourist attractions want to open, and theyre waiting on rules from Gov. Mike DeWine. Cleveland.com editors are talking about how youd make the attractions safe amid the coronavirus on This Week in the CLE, the daily half-hour podcast.

New numbers: At least 2,098 Ohioans have died with confirmed or probable coronavirus by Thursday, Laura Hancock reports. The state now has at least 33,915 probable and confirmed cases of COVID-19.

Cleveland numbers: Mayor Frank Jacksons administration announced Thursday that 50 more Clevelanders were confirmed as having contracted the COVID-19 coronavirus, bringing to nearly 1,900 the total number of confirmed and probable cases of the virus in Cleveland, Robert Higgs reports. No new deaths were reported.

Ohio reported its first three cases of coronavirus on March 9. On Thursday, the total reached 33,915.Rich Exner, cleveland.com

Trends: Ohios 2,098 known coronavirus-related deaths are spread across 68 of the states 88 counties, Rich Exner reports. The death total increased 2.6%, while the case total was up 1.4%.

Nursing homes: At least 1,442 patients of Ohio nursing homes and other long-term care facilities have died with coronavirus, accounting for 70% of the states known COVID-19 deaths, reports Rich Exner. The high mortality numbers for nursing homes have drawn increasing attention from state officials, with Gov. Mike DeWine announcing this week that the National Guard would be used to begin testing all staff at nursing homes across Ohio.

Unemployment: Ohio reported a decline in new unemployment claims for the eighth straight week of the coronavirus crisis, but another 2.1 million claims were filed across the U.S., reports Evan MacDonald. Ohio received 42,082 new unemployment claims for the week ending May 23.

No-longer-daily briefings: Gov. Mike DeWines coronavirus briefings are becoming shorter and less often, reports Laura Hancock. The comforting news conferences, affectionally known as Wine with DeWine, have morphed from daily 90-minute events into twice-a-week, 60-minute briefings. But DeWine is still sporting spirited ties.

Cold immunity: Scientists are examining whether people whove had another strain of the coronavirus one that causes the common cold could have some immunity to protect against the deadly coronavirus. Mary Kilpatrick reports on the latest science and studies, including that 42 percent of cases in a group studied in Wuhan, China, were asymptomatic.

ARDS: Experts hope a type of stem cells could play a key role in managing one of the most severe conditions caused by the coronavirus, acute respiratory distress syndrome. Evan MacDonald reports the Cleveland Clinic is among 15 health systems participating in a clinical trial on whether mesenchymal stromal cells could help treat the inflammation of the lungs.

County fairs: Ohio will allow junior county fairs to take place this summer, with a focus on youth programs including 4-H and FFA, Laura Johnston reports. Livestock shows and auctions can take place, as well as art and other exhibits and food sales.

E-Check: State officials have reopened E-Check stations in Northeast Ohio after they were closed for more than two months due to the coronavirus pandemic, reports Andrew Tobias. Officials issued a six-month extension on E-Check requirements to all motorists whose vehicle renewal was due from February through July.

CVS is opening more self-swab coronavirus testing sites today in Ohio, including several locations in Northeast Ohio. (CVS)

CVS testing: Thirty-four additional testing sites for the COVID-19 coronavirus will open today at CVS stores in Ohio, including several locations in Northeast Ohio, reports Cliff Pinckard. CVS says it hopes to have 1,000 testing sites open across the country by the end of the month.

Test criteria: Ohio broadly expanded the criteria for determining who is allowed to get a coronavirus test to include Ohioans who are showing symptoms of the disease. Before now, sick people who suspected they had COVID-19 were frequently denied tests, Laura Hancock reports.

Youngstown prison: A federal judge said that staff at a private prison in Youngstown were doing enough to prevent the spread of the coronavirus among inmates, rebutting an opinion from a doctor who said conditions could lead to a significant outbreak, reports Eric Heisig. U.S. District Judge Solomon Oliver said he would not order staff at the Northeast Ohio Correctional Center to implement recommendations made by Dr. Venktesh Ramnath. While four staff members have tested positive for the virus, no inmates have, the judge noted.

Elkton prison: In an unprecedented move, dozens of current and former top prosecutors and police chiefs urged a federal appeals court late Thursday to push for the release and transfer of inmates at a prison in Ohio, where nine inmates have died and hundreds have been infected by the coronavirus, John Caniglia reports.

Edgewater chase: Cleveland Metroparks police arrested two men after officers chased a stolen SUV that police connected to several violent crimes in Cleveland, Adam Ferrise reports. Metroparks police arrested two 18-year-old men on suspicion of leading police on a 14-mile winding chase on the citys West Side.

Bulk refuse: Cleveland plans to bring back bulk pickup of refuse after two months of it being sidelined by the coronavirus pandemic, although the city has not yet settled on which week in late June pickups will be restarted, Robert Higgs reports. The bulk pickup service is for large items such as furniture, appliances and old tires.

Legal immunity: Controversial legislation to temporarily grant legal immunity to Ohio businesses particularly nursing homes and other healthcare providers for transmitting the coronavirus passed the Ohio House Thursday. Jeremy Pelzer reports the House tacked on an amendment that would make prison staff, grocery-store workers, and first-responders eligible for workers compensation should they catch the virus.

The Ohio House of Representatives has approved a bill that would legalize betting on sports within the state. (Edward Pevos, mlive.com file photo)

Sports betting: Betting on sports is one step closer to becoming legal in Ohio after the Ohio House of Representatives on Thursday approved a gambling bill thats been debated in the Statehouse for over a year. Andrew Tobias reports House Bill 194 would put the Ohio Lottery Commission in charge of regulating sports betting, tax receipts at 10% and send proceeds to education and gambling-addiction programs.

To-go cocktails: Calling cocktails to-go a "much needed lifeline" that restaurants and bars can use to help sustain their business during coronavirus restrictions, the Distilled Spirits Council of the United States urged lawmakers in Columbus to make the measure permanent, Marc Bona reports.

Police chase lawsuit: The family of a 13-year-old girl killed when teenage carjacking suspects jumped the curb and struck her during a high-speed police chase has filed a wrongful death lawsuit against the Cleveland police department and several officers involved. Cory Shaffer reports Tamia Chappmans family argue 22 officers acted recklessly in the Dec. 20 pursuit.

Coronavirus scam: Officials are warning the public after a group of sophisticated crooks scammed a woman out of more than $1,000 by posing as Cuyahoga County Sheriff's Department employees and convincing her to pay money over the phone to avoid arrest for missing jury duty. Cory Shaffer reports the con-artists succeeded in part because of the alarming level of detail they had about the woman.

Appeals court: The Ohio Supreme Court affirmed that an appeals court does not have jurisdiction to hear a petition by the city of East Cleveland related to the 137 shots police chase that killed two unarmed people. Evan MacDonald reports the high court affirmed that the 8th Ohio District Court of Appeals could not hear East Clevelands petition for declaratory judgment.

Content Marketing World: Content Marketing World, Clevelands largest recurring business-to-business event, is offering participants the chance to attend online this year due to the coronavirus pandemic. Mary Kilpatrick reports the conference will allow participants to register for online access to its offerings, at a discounted rate.

Great Lakes cruises: Victory Cruise Lines, the biggest player in Great Lakes cruising, has canceled its 2020 sailing season, leaving Cleveland without cruise passengers this summer. Susan Glaser reports Victory, which typically sails two ships in the Great Lakes during a six-month season, was scheduled to resume its itineraries in early July.

Tuesday Morning: Several Northeast Ohio Tuesday Morning stores are among those that the company will close as a result of its Chapter 11 bankruptcy filing, Marc Bona reports.

Cedar Point: Visitors to Cedar Point this summer will be able to use their smartphone to reserve entry, fill out a health survey, and see which areas of the park are most crowded during their visit. Susan Glaser reports guests will be able to make a reservation for a specific day and time to visit the park, based on capacity.

Lake Erie Ink: Cleveland teen writing program Lake Erie Ink will release its fourth anthology of writing and art in June, featuring submissions by young local writers and artists, Anne Nickoloff reports. The book, titled The Fundamental Elements, includes works by more than 60 teens and a foreword by Cleveland poet Philip Metres.

The Rail: The Rail has closed its North Olmsted and Canton locations. Marc Bona reports the burger- and craft-beer-centric restaurant called the decision to close "very difficult" and said employees from both locations have been offered a transfer to nearby Rails.

Ventilators: MIT has designed an emergency ventilator that uses commonly found and easily sourced materials. Cleveland.coms sister site, WIRED, shows how a cheaper alternative may be able to save lives.

Things to do: Hoping to check out an event or try a new adventure this weekend in Greater Cleveland? Anne Nickoloff has 15 ideas for safe activities, from a virtual music festival to strolling Holden Arboretum.

Ohio Statehouse damaged during protests in Columbus over death of George Floyd Read more

Coronavirus reopenings, cancellations and delays in Northeast Ohio for Friday, May 29, 2020 Read more

Struggling Akron-Canton Airport asks for money to bring back flights Read more

Man shot to death in school parking lot in Clevelands Tremont neighborhood Read more

Man shot in Clevelands West Boulevard neighborhood dies, police say Read more

Men barge into Brook Park home, hold brothers at gunpoint, reports say Read more

Police: Gunman killed teen driving home from playing soccer, man on porch in five minutes in Cleveland Read more

Rapist in Lake County sentenced to 136 years in prison Read more

Akron Zoo announces plan to reopen once Ohio lifts coronavirus-related restrictions on zoos Read more

Rubber worker statue to be installed in downtown Akron in early September Read more

Akron Childrens Hospital to open Ravenna pediatric center on June 2 Read more

Chagrin Falls school board OKs $330,000 in personnel cuts; College Credit Plus saved Read more

Motorcyclist seriously injured in Lorain County crash, officials say Read more

Berea City Schools 5-year forecast shows deficit spending Read more

Parma Heights cancels youth baseball/softball program and city events, closes pool and tennis courts Read more

Ridgewood Golf Course schedules social distancing-friendly junior golf program Read more

See the rest here:
How safe are Ohio summer fun activities amid the coronavirus threat? The Wake Up for Friday, May 29, 2020 - cleveland.com

Posted in Ohio Stem Cells | Comments Off on How safe are Ohio summer fun activities amid the coronavirus threat? The Wake Up for Friday, May 29, 2020 – cleveland.com

Kenneth Wallace Promoted to Full Professor at Clarkson University – Clarkson University News

Posted: May 31, 2020 at 2:46 pm

Kenneth Wallace

Clarkson University President Tony Collins has announced that Kenneth Wallace has been promoted from associate professor to full professor of biology in the School of Arts & Sciences. Promotion to professor is considered to be virtually the highest honor that a university can bestow upon its faculty.

Wallace's research focuses on the development of the digestive system and effects of nanoparticles exposure. Wallace uses zebrafish, which are an excellent model research organism, with extensive similarities to the genetics and physiology of human organ development with broad implications for human development and disease states.

The intestinal epithelium continuously replaces cells that undergo apoptosis. Cells proliferate in the crypts at the base of the villi to replace lost epithelial cells. While there is intense investigation into the signals controlling proliferation of crypt epithelial cells, little is known about the formation of the developing stem cell niche. Wallace is investigating epithelial cells that play a role in regulation proliferation of the developing stem cell niche using zebrafish as a model system.

Wallace's research also investigates the effects of nanoparticle exposure using the zebrafish model system in collaboration with Chemistry Professor Silvana Andreescu. Developmental defects and physiological changes are assessed following exposure to nanoparticles with different physiochemical properties. Electrochemical sensors developed in Dr. Andreescus lab are used to detect nitric oxide and reactive oxygen species following exposure.

Wallace has published numerous highly cited papers and has delivered presentations at many international conferences. He is currently funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development at the National Institutes of Health. He was previously funded by the National Institute if Diabetes and Digestive and Kidney Diseases as well as the NSF. He was inducted to the million dollar club in 2019 (Clarkson). Wallace has mentored 12 graduate students and 50 undergraduates in research.

Wallace has been a faculty member in the Department of Biology at Clarkson since 2004. Prior to that he was a postdoctoral fellow at the University of Pennsylvania Department of Medicine.

He received his Ph.D. in molecular genetics from Ohio State University and his bachelor of science degree in molecular genetics from the University of Rochester.

Continued here:
Kenneth Wallace Promoted to Full Professor at Clarkson University - Clarkson University News

Posted in Ohio Stem Cells | Comments Off on Kenneth Wallace Promoted to Full Professor at Clarkson University – Clarkson University News

Page 1,001«..1020..1,0001,0011,0021,003..1,0101,020..»